Karolinska Development AB (publ) (FRA:2I9)
Germany · Delayed Price · Currency is EUR 0.0437
-0.0010 (-2.24%)
At close: Nov 28, 2025
Karolinska Development AB Company Description
Karolinska Development AB (publ) is a venture capital firm specializing in investments in growth capital, seed stage, and early stage companies.
It seeks to invest in pharmaceutical research and development, medical research, medical innovations, healthcare technology, gene research and development, drug delivery technologies, biotechnology, and life science tools and service sectors.
The firm seeks to invest in the Nordic region with a focus on Sweden, Iceland, Norway, Finland, and Denmark.
It prefers to be a lead investor in its portfolio companies however does consider co-investments also.
It seeks to invest in up to five projects annually. Karolinska Development AB (publ) was founded in 2003 and is headquartered in Stockholm, Sweden.
Karolinska Development AB (publ)
| Country | Sweden |
| Founded | 2003 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 8 |
| CEO | Viktor Drvota |
Contact Details
Address: Nanna Svartz väg 6A Solna, 17165 Sweden | |
| Phone | 46 8 524 860 70 |
| Website | karolinskadevelopment.com |
Stock Details
| Ticker Symbol | 2I9 |
| Exchange | Frankfurt Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Viktor Drvota | Chief Executive Officer |
| Hans Toll | Chief Financial Officer |